Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 1.1 -0.01 (-0.9%) Market Cap: 281.12 Mil Enterprise Value: 163.71 Mil PE Ratio: 0 PB Ratio: 11.00 GF Score: 66/100

Full Year 2023 Adaptimmune Therapeutics PLC Earnings Call Transcript

Mar 06, 2024 / 01:00PM GMT
Release Date Price: $1.71 (+17.12%)
Operator

Hello, and welcome to Adaptimmune fourth quarter and year end conference call and business update.

I will now turn the call over to Juli Miller. Juli, please go ahead.

Juli P. Miller
Adaptimmune Therapeutics PLC - VP of Corporate Affairs & IR

Good morning, and thank you for joining us. Welcome to our Q4 and full year 2023 update, and I refer you to our disclaimer here. As well as our forward-looking statements in this morning's press release. For the prepared portion of the call, Adrian Rawcliffe, our CEO, is with us and other members of our management team are available for Q&A.

With that, I'll turn the call over to Adrian.

Adrian Rawcliffe
Adaptimmune Therapeutics PLC - CEO

Thanks Juli. Thanks everyone, for joining today. So, I plan today to recap the progress we made in 2023 and shared a little bit about our plans for 2024. I'll be focused primarily on afami-cel, which will be our first commercial product in our sarcoma franchise. 2023 was a year of transformation for Adaptimmune. We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot